Please login to the form below

Not currently logged in
Email:
Password:

Orexo hires new CEO as Biolipox acquisition closes

The board of directors of Swedish pharmaceutical company Orexo appoints Torbjoern Bjerke as new CEO of the company

The board of directors of Swedish pharmaceutical company Orexo has appointed Torbjoern Bjerke as new CEO of the company.

The appointment was announced at the same time as Orexo revealed it had finally acquired Biolipox.

Orexo has acquired all shares and warrants in Biolipox through payment consisting of 7,630,895 new shares in Orexo and 926,000 warrants allowing subscription for 926,000 new shares in Orexo.

Bjerke was previously CEO in Biolipox. As previously announced, Zsolt Lavotha, Orexo's former CEO, will leave his post and serve as Senior Advisor to Orexo's board.

The board of directors of Orexo has also prepared a prospectus regarding listing of shares in Orexo in connection with the acquisition of Biolipox.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics